Maxim Group Upgrades Galmed Pharmaceuticals to Buy, Announces $4 Price Target
Portfolio Pulse from richadhand@benzinga.com
Maxim Group analyst Jason McCarthy has upgraded Galmed Pharmaceuticals (NASDAQ:GLMD) from Hold to Buy and set a price target of $4.
July 24, 2023 | 12:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Galmed Pharmaceuticals has been upgraded to Buy from Hold by Maxim Group, with a new price target of $4.
The upgrade from Hold to Buy by Maxim Group indicates a positive outlook for Galmed Pharmaceuticals. The new price target of $4 also suggests potential upside, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100